U.S. Post Office’s loss nearly triples, while sales edge higher

The U.S. Postal Services reported a fiscal third-quarter loss that widened to $1.57 billion from $586 million a year ago. The widening was due primarily to a $1.6 billion unfavorable change in workers’ compensation expense as a result of interest rate changes. Revenue rose 7.1% to $17.7 billion, but was reduced by about $450 million by the expiration of an exigent surcharge. Total volume declined 0.2% to 36.73 billion pieces, as a 1.7% increase in standard mail volume, a 14% increase in shipping and packages and 5% growth in international was offset by a 3.4% decline in first-class mail and a 3.8% drop in periodicals. “Although the Postal Service achieved strong results in package delivery and Standard Mail volumes, only a slight increase in total revenue was recorded due to a mandated price reduction earlier this year,” said Chief Financial Officer Joseph Corbett. “We incurred a net loss resulting, in part, from continued decreases in first-class mail volume and systemic financial imbalances associated with our retiree health benefit prefunding requirements.”

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Impax Laboratories stock plunges as competition pushes results well below expectations

Impax Laboratories Inc.’s stock plunged 26% in premarket trade, putting it on track to open at a near two-year low, after the drugmaker’s second-quarter results fell well short of expectations. Losses for the latest quarter widened to $2.7 million, or 4 cents a share, from $1.9 million, or 3 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to 21 cents, missing the FactSet consensus of 32 cents. Revenue fell to $172.6 million from $214.2 million, due primarily because of a 30% decline in generics revenue, to miss the FactSet consensus of $223.7 million. “Our second quarter results reflect the unexpected and rapid decline in sales of diclofenac and metaxalone as a result of additional competition,” said Chief Executive Fred Wilkinson. “In particular, the change in the diclofenac market quickly moved us from an exclusive supplier position to a five competitor market.” The stock had tumbled 28% year to date through Monday, while the SPDR S&P Biotech ETF has lost 10% and the S&P 500 has gained 6.7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Press Ganey to be acquired by private-equity firm EQT in $2.35 billion deal

Press Ganey , which offers performance analytics to health care companies, said it has entered an agreement to be acquired by private-equity firm EQT in a deal with an enterprise value of about $2.35 billion. EQT will pay $40.50 in cash per Press Ganey share, for a 20% premium of the stock’s year-to-date volume-weighted average price, or a 62% premium over its initial pubic offering issue price. The deal is expected to close in the fourth quarter. Press Ganey shares were flat in premarket trade, but have gained 28% in the year to date, while the S&P 500 has gained about 7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Norwegian Cruise’s stock tumbles after downbeat profit outlook

Shares of Norwegian Cruise Line Holdings Ltd. tumbled 8.1% in premarket trade Tuesday, after the cruise operator reported a second-quarter profit that beat expectations, but provided a downbeat outlook. Earnings fell to $145.2 million, or 64 cents a share, from $158.5 million, or 69 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came in at 85 cents, beating the FactSet consensus of 83 cents. Revenue rose to $1.19 billion from $1.09 billion, but was below the FactSet consensus of $1.22 billion, as weaker-than-expected passenger ticket revenue offset a beat in onboard and other revenue. Looking ahead, third-quarter adjusted EPS is expected to be $1.57 to $1.62, below the FactSet consensus of $1.78. Citing continued weak demand from North American consumers and a weaker British pound following the Brexit vote, the company no longer expects to achieve its 2017 adjusted EPS target of $5.00.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Wayfair shares sink after losses exceed estimates

Wayfair Inc. shares dropped 9.4% in Tuesday premarket trading after the online home furnishings company reported second-quarter losses that exceeded estimates. Wayfair reported a net loss of $48.27 million, or 57 cents per share, compared with a loss of $19.33 million, or 23 cents per share, for the same period last year. Adjusted losses were 43 cents per share while the FactSet consensus was for a loss of 40 cents per share. Revenue for the quarter totaled $786.93 million, up from $491.75 million for the same period last year and exceeding the $782 million FactSet consensus. Wayfair shares are up 32.1% for the past year while the S&P 500 Index is up 5% for the same period.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Array BioPharma shares fall 11% premarket after lung cancer drug trial fails to meet goals

Shares of Array BioPharma Inc. slumped 11% in premarket trade Tuesday, on news that a late-stage trial of a treatment for lung cancer failed to meet its primary goal. The news was revealed by AstraZeneca which owns the exclusive rights to the drug from Array. It said the Phase III trial of selumetinib, in combination with docetaxel chemotherapy as a second-line treatment in patients with KRAS mutation-positive locally-advanced or metastatic non-small cell lung cancer failed to meet its primary endpoint. Array has received $26.5 million in upfront and milestone payments for the drug and could earn up to $70 million more in milestone payments and royalties. Last week, Bristol-Myers Squibb Co. said its lung cancer treatment failed a late-stage trial, sending its stock sharply lower. AstraZeneca shares were down 1.5%. S&P 500 futures were up 0.1%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Gap Inc. shares fall in premarket trading after reporting same-store sales declines

Gap Inc. is down 6.3% in Tuesday premarket trading in the wake of disappointing July and second-quarter same-store sales at the Banana Republic and namesake brands. Old Navy reported flat same-store sales for the month and the quarter. Overall, Gap Inc. reported a 4% same-store sales decline for the month, and a 2% same-store sales decline for the second quarter. “Unfavorable weather, soft traffic trends and uninspiring product assortments contributed to the disappointing results,” wrote Stifel analysts on Monday. The bank believes there will be continued challenges in the near-term. “The prolonged underperformance at the Gap businesses despite management’s best efforts has undermined our confidence and limited our visibility for improvement,” Stifel said. Analysts maintained their hold rating on Gap shares. Gap shares are down 26.6% for the past year, but up 3.7% for the year to date. The S&P 500 Index is up 6.7% for the year so far.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Coach’s stock surges after profit, North American sales beat expectations

Coach Inc.’s stock surged 2.4% in premarket trade Tuesday, after the luxury accessories retailer reported fiscal fourth-quarter earnings that beat expectations. Earnings for the quarter ended July 2 rose to $81.5 million, or 29 cents a share, from $11.7 million, or 4 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to 45 cents, beating the FactSet consensus of 41 cents. Revenue increased to $1.15 billion from $1.00 billion, just shy of the FactSet consensus of $1.16 billion. North American sales rose 9% to $606 million, above the FactSet consensus of $591.8 million, while domestic same-store sales grew 2% to beat expectations of 1.8%. Stuart Weitzman sales came in at $84 million, above the FactSet consensus of $81.6 million. For fiscal 2017, Coach expects revenue to increase in the low-to-mid single digit percentage range, while the current FactSet consensus of $4.68 billion implies 4.1% growth. The stock has soared 27% year to date through Monday, while the S&P 500 has gained 6.7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Valeant jumps 9% premarket after sticking to full-year guidance

Shares of Valeant Pharmaceuticals International Inc. rallied 9% in heavy premarket trade on Tuesday after the drug maker reported a wider loss in the second quarter, but confirmed its full-year guidance. The company said it lost $302.3 million during the quarter, or 88 cents a share, compared with a loss of $53 million, or 15 cents a share, in the year ago period. On an adjusted basis, earnings came in at $1.40 a share, down from $2.14 a share last year. Revenue fell 11% to $2.42 billion. Valeant said it still expects revenue for the full year to be in the range of $9.9 billion to $10.1 billion. It also confirmed its adjusted-earnings forecast of $6.60 to $7.00 a share.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

U.K. 10-year bond yields slide to fresh record low

Interest rates on U.K. government debt dropped to a fresh all-time low on Tuesday, as investors continued to digest the Bank of England’s aggressive stimulus package unveiled last week. The yield on 10-year Gilts fell 9 basis points to 0.591%, breaking below 0.60% for the first time ever. U.K. borrowing costs have been falling steadily since the country’s Brexit vote in June and on Thursday last week, yields took another dive after the BOE meeting. The central bank cut its interest rate to a record low of 0.25%, restarted its asset purchase program, and announced plans for corporate bond buys and ultracheap funding for banks. The measures have also weighed on the pound, which continued to slide on Tuesday. Sterling bought $1.2999, down from $1.3040 late Monday in New York. Against the euro [s:gbpeur], the pound dropped to €1.1722 compared with €1.1760 on Monday.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News